Case Report
PTH-Related Protein Assays in Advanced Kidney Disease: Implications for Evaluation of Hypercalcemia
Table 1
Serum chemistries during the 3-month phase of hypercalcemia.
| | 12/6/20 | 1/7/21 | 2/4/21 | 2/7/21 | 2/27/21 | 3/4/21 | 3/9/21 | 3/11/21 | 3/16/21 | 4/8/21 |
| Ca (mmol/L) normal 2.18–2.58 | 1.85 | 2.62 | 2.74 | | 2.62 | 2.74 | 2.77 | 2.77 | 2.67 | 2.67 | Phos (mmol/L) normal 0.81–1.45 | 1.26 | 1.65 | 2 | | | 1.71 | | 1.65 | 1.81 | 1.48 | 25(OH)D normal 74.9–249.6 | | | | | | | | 54.91 | | | 1,25(OH)2 (pmol/L) normal 50.4–156.0 | | | | | | | | <12 | | | iPTH (pmol/L), C-terminal normal 1.6–9.3 | 1.59 | <0.64 | <0.64 | | | | | | | <0.64 | Albumin (mmol/L) normal 0.87–1.25 | 0.42 | | | | | | | | 0.65 | | Light chain ratio | | | | | | | | | 1.96 | | Ionized calcium (mmol/L) normal 1.05–1.3 | 0.29 | | | | | | | | | | PTHrP (pmol/L) normal 33.6–64.8 | | | | | | | | | 110.4 | |
|
|